Share on LinkedInShare on LinkedIn

ARTICLE · 26 MAY 2004

To Negate Public Use Bar Experimental Use Must Be Limited to Perfecting Claimed Features

Reversing the district court’s erroneous claim construction, the U.S. Court of Appeals for the Federal Circuit held that Apotex’s product infringed SmithKline Beecham’s (now GlaxoSmithKline’s) claim covering the active ingredient of the antidepressant Paxil, but further held the claim invalid because SmithKline’s clinical tests prior to one year before filing constituted a public use not qualifying under the experimental use exception.

United StatesIntellectual Property

Reversing the district court’s erroneous claim construction, the U.S. Court of Appeals for the Federal Circuit held that Apotex’s product infringed SmithKline Beecham’s (now GlaxoSmithKline’s) claim covering the active ingredient of the antidepressant Paxil, but further held the claim invalid because SmithKline’s clinical tests prior to one year before filing constituted a public use not qualifying under the experimental use exception. SmithKline Beecham Corp. v. Apotex Corp., Case Nos. 03-1285, -1313 (Fed. Cir. Apr. 23, 2004) (Rader, J.) (Gajarsa, J., dissenting) (errata, Apr. 28, 2004).

Claim 1 of SmithKline’s U.S. Pat. No. 4,721,723, recites, in its entirety, "Crystalline paroxetine hydrochloride hemihydrate" (PHC hemihydrate), which is the active ingredient of SmithKline’s antidepressant drug Paxil. Apotex filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA), seeking approval to market its own PHC antidepressant drug. Apotex identified

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from